SMAD2 and myelodysplastic syndrome: Interestingly, studies have demonstrated that pharmacological inhibition of TGF‐β receptors or suppression of SMAD2/3 activity using short hairpin RNA can enhance haematopoiesis across various MDS subtypes in vitro.